• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care

    1/22/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    ROANOKE, Va. and FRANKLIN LAKES, N.J., Jan. 22, 2025 /PRNewswire/ -- Carilion Clinic, a not-for-profit health care organization serving more than 1 million people in Virginia, in partnership with BD, (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Carilion is the first health system in the state and the Southeastern U.S. to provide its patients needle-free blood draws using the BD® PIVO™ Pro Needle-free Blood Collection Device. This initiative is part of Carilion's commitment to patient-centered care, delivering on the vision of a "One-Stick Patient Experience" by reducing multiple needlesticks while improving the quality of care.

    Carilion Clinic is the first health system in Virginia to to provide its patients needle-free blood draws, redefining the patient standard of care.

    The advanced PIVO™ Pro Technology allows clinicians to use a patient's existing peripheral IV catheter line for blood draws, leading to fewer needlesticks and less pain and anxiety for many patients. It also reduces the risk of needlestick injuries and streamlines clinical workflows, minimizing traditional IV and blood collection complications that result in redraws and potential delays in patient care.1,2

    "We are excited to be the first in Virginia to implement this novel needle-free blood draw technology, marking a significant improvement in our vascular access practices and enhancing patient outcomes and satisfaction," said Tami Frost, MSN, RN, CENP and chief nursing officer at Carilion. "By streamlining blood draws through our new specialty vascular access team, we will save our bedside nurses valuable time, allowing them to focus on other critical aspects of patient care."

    Traditional blood draws by venipuncture are one of the most common hospital procedures, affecting nearly every hospitalized patient daily.3 A recent Harris Poll highlighted that patients often experience unnecessary, failed and repeat needlesticks in hospitals. In fact, needlesticks are an often-overlooked challenge but can be one of the most traumatic aspects of a patient's hospital stay with more than half of Americans (51%) reporting some fear of needles. Among those, a top reason is fear of needing multiple needle insertions (31%).  

    Patients and clinicians alike are interested in new technology and solutions to reduce needlesticks and improve the standard of care. 

    "During my hospital stay, I dreaded the daily blood draws that left my arms bruised and painful," said a 17-year-old pediatric patient who experienced PIVO™ Pro during Carilion's trial period. "When I was introduced to this device, it was a game-changer. It saved me from the pain and tears of multiple needlesticks. It truly transformed my hospital experience, allowing me to focus on getting better without the added stress of painful blood draws. This innovation gave me hope and comfort during a very challenging time."

    PIVO™ Pro will be available at Carilion Roanoke Memorial Hospital and will be rolled out to other Carilion hospitals throughout the year. Learn more about Carilion's commitment to compassionate patient care at www.carilionclinic.org. 

    As the global leader in vascular access solutions, BD is committed to advancing the standard of care for IV therapy and blood draws for patients and health care providers. The PIVO™ Pro technology is part of the company's vision for a "One-Stick Patient Experience" to help minimize the number of needlesticks for patients by using an existing peripheral IV catheter line to collect a high-quality, reliable blood sample through a singular access point.1 For more information about the BD Peripheral Line Draw Solution, including PIVO™ Pro, visit www.bd.com/PIVO. 

    About Carilion Clinic 

    Carilion Clinic is a private, not-for-profit healthcare organization headquartered in Roanoke, Va. A comprehensive network of hospitals, primary and specialty physician practices and other complementary services enables employees to collaborate in providing quality care close to home for nearly 1 million Virginians. With an enduring commitment to the region's health and wellness, Carilion also advances care through philanthropy, medical education and research, helps the communities it serves stay healthy and inspires the region to grow stronger. For more information, visit CarilionClinic.org and follow us on Facebook, X (formerly Twitter), Instagram, LinkedIn and YouTube.

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

    Contacts

    Carilion Clinic Corporate Communications

    540-525-6041

    [email protected]  

    Alyssa Kretlow

    BD Corporate Communications

    551.238.4391

    [email protected] 

    Sources:

    1. Pendleton B, LaFaye R. Multicenter study of needle-free blood collection system for reducing specimen error and intravenous catheter replacement. J Healthc Qual. 2022;44(2):e24-e30. doi:10.1097/JHQ.0000000000000331.
    2. Green SF. The cost of poor blood specimen quality and errors in preanalytical processes. Clin Biochem. 2013;46:1175-1179. doi: 10.1016/j.clinbiochem.2013.06.001.
    3. Cadacio C, Nachamkin I. A novel needle-free blood draw device for sample collection from short peripheral catheters. J Infus Nurs. 2017:40(3):156-162.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/carilion-clinic-first-in-virginia-to-offer-needle-free-in-patient-blood-draws-redefining-patient-standard-of-care-302356789.html

    SOURCE BD (Becton, Dickinson and Company)

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    4/10/2026$167.00Neutral
    Goldman
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    4/9/26 4:18:47 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    4/2/26 4:18:23 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/25/26 4:25:34 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Becton Dickinson with a new price target

    Goldman resumed coverage of Becton Dickinson with a rating of Neutral and set a new price target of $167.00

    4/10/26 12:23:31 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Becton Dickinson with a new price target

    Citigroup resumed coverage of Becton Dickinson with a rating of Buy and set a new price target of $233.00

    2/3/26 6:55:14 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Neal Shana Carol

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    4/6/26 5:28:51 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Feld Michael

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    3/27/26 1:49:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    EVP and General Counsel Minnix Lanesha was granted 7,492 shares (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    3/17/26 2:46:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD Earns Industry Top Honors for Transparency, Resiliency and Partnership

    FRANKLIN LAKES, N.J., April 16, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, has been recognized by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive HIRC's inaugural Member Choice Awards across three categories, Transparency, Resiliency and Partnership. Selected by HIRC members based on real–world customer experience, the awards acknowledge suppliers whose actions strengthen supply chain transparency, resilience, and continuity of patient care. Transparency Award: recognize

    4/16/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD to Announce Financial Results for its Second Quarter of Fiscal 2026

    FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 7, 2026 to discuss the Company's financial results for its second quarter of fiscal year 2026, which ended on March 31, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will inclu

    4/9/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Rick Byrd to Retire from BD

    FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD. Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joini

    4/9/26 4:05:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

    FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share. The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations pr

    1/27/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care